RG7334: Phase Ib discontinued

BioInvent said partner Roche discontinued a Phase Ib trial evaluating RG7334 plus Nexavar sorafenib in up to 70 patients. According to BioInvent, Roche concluded that slow recruitment in the first part of the trial would make completing the second, randomized part of the trial difficult. ...